arrow
T

Taigo Kato

University of Osaka
H指数:33
被引数:3,198

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TFEB drives ER stress-induced apoptosis and limits cyst growth in polycystic kidney disease

TFEB驱动内质网应激诱导的凋亡并限制多囊肾病的囊肿生长

2026-10-140
OAAI
COMPOUND LIBRARY SCREENING IDENTIFIED NOVEL RADIOSENSITIZERS FOR PROSTATE CANCER

前列腺癌新型放射增敏剂的化合物库筛选鉴定

2026-05-010
PRE
Compound Library Screening Identified Cladribine as a Novel Radiosensitizer for Prostate Cancer
2026-01-190
OAAI
Successful Stereotactic Body Radiation Therapy for Prostate Cancer in a Patient With Prior Total Colectomy and Ileal Pouch-Anal Anastomosis: A Case Report and Technical Considerations

前列腺癌患者行全结肠切除和回肠储袋肛管吻合术后成功实施立体定向体部放射治疗的病例报告及技术考量

2025-12-010
OA
Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate Cancer

基于LIG1和PARP抑制剂的合成致死性联合疗法在前列腺癌中的开发

2025-09-160
OAAI
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire

从多样化的肿瘤携带者T细胞受体库中选择具有治疗效果的T细胞受体

2025-05-020
OA
Real-world outcomes with avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification

日本晚期肾细胞癌患者接受阿维鲁姆单抗联合阿昔替尼治疗的实际世界结局:基于国际转移性肾细胞癌数据库联盟风险分类的J-DART2研究亚组分析

2025-02-110
OA
A novel mouse model of upper tract urothelial carcinoma highlights the impact of dietary intervention on gut microbiota and carcinogenesis prevention despite carcinogen exposure
2024-12-180
OA
Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up of the East Asian subgroup of the randomized phase III LITESPARK-005 trial

Belzutifan与everolimus对比用于既往治疗过的晚期透明细胞肾细胞癌(ccRCC):随机III期LITESPARK-005试验东亚亚组的更新随访

2024-12-010
PRE
GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment

GDF15前肽通过增强骨微环境促进去势抵抗性前列腺癌骨转移

2024-11-250
OAAI
A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study

一项关于PARP抑制剂(niraparib)联合HSP90抑制剂(pimitespib)在实体瘤中的I期研究:NiraPim(EPOC2102)研究

2024-09-010
PRE
Novel clinical decision support (CDS) system optimizing adjuvant chemotherapy (ACT) for colorectal cancer (CRC) by integrating deep learning and circulating tumor DNA (ctDNA) molecular residual disease (MRD): GALAXY histotyping

新型临床决策支持(CDS)系统,通过整合深度学习与循环肿瘤DNA(ctDNA)分子残留病灶(MRD)优化结直肠癌(CRC)辅助化疗:GALAXY组织分型

2024-09-010
PRE